Literature DB >> 23692434

HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese.

Ying-Kit Cheung1, Suk-Hang Cheng, Ernest J M Chan, Su V Lo, Margaret H L Ng, Patrick Kwan.   

Abstract

PURPOSE: HLA-B*15:02 screening is recommended before starting carbamazepine in Han Chinese and Southeast Asians because the allele is strongly predictive of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) induced by the drug. We examined whether other HLA-B alleles are also involved and whether the association extends to other antiepileptic drugs (AEDs).
METHODS: Cases of SJS/TEN induced by any AEDs were recruited and matched (1:5) with AED-tolerant controls. Carrier rates of HLA-B alleles, determined by direct sequencing, were compared between cases and controls. Results were meta-analyzed with previous studies to examine the associations between HLA-B*15:02 and SJS/TEN induced by phenytoin and lamotrigine. KEY
FINDINGS: A total of 55 cases (27 carbamazepine, 15 phenytoin, 6 lamotrigine, 7 other AEDs) and 275 controls were recruited. In drug-specific analysis, the carrier rate of HLA-B*15:02 was significantly higher in carbamazepine-SJS/TEN cases compared with carbamazepine-tolerant controls (92.3% vs. 11.9%; p = 3.51 × 10(-18) ; odds ratio (OR) 89.25; 95% confidence interval (CI) 19.25-413.83), and also in phenytoin-SJS/TEN cases compared with phenytoin-tolerant controls (46.7% vs. 20.0%; p = 0.045; OR 3.50; 95% CI 1.10-11.18). Meta-analyses showed a strong association of HLA-B*15:02 with phenytoin-SJS/TEN (p < 3 × 10(-4) ; OR 4.26; 95% CI 1.93-9.39) and, to a lesser extent, lamotrigine-SJS/TEN (p = 0.03; OR 3.59; 95% CI 1.15-11.22). Compared with drug-tolerant controls, the carrier rates of HLA-B*40:01 and HLA-B*58:01 were lower in cases of SJS/TEN induced by carbamazepine (p = 0.004) and other AEDs (p = 0.009), respectively. SIGNIFICANCE: SJS/TEN induced by carbamazepine and phenytoin is strongly and moderately associated with HLA-B*15:02 in Han Chinese, respectively. Possible protective associations with HLA-B*40:01 and HLA-B*58:01 warrant further investigation. Wiley Periodicals, Inc.
© 2013 International League Against Epilepsy.

Entities:  

Keywords:  Antiepileptic drugs; Human leukocyte antigen; Pharmacogenetics; Stevens-Johnson syndrome; Toxic epidermal necrolysis

Mesh:

Substances:

Year:  2013        PMID: 23692434     DOI: 10.1111/epi.12217

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  52 in total

1.  Phenytoin Hypersensitivity: It's Time for Some Individuality.

Authors:  Barry E Gidal
Journal:  Epilepsy Curr       Date:  2015 Jul-Aug       Impact factor: 7.500

Review 2.  Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.

Authors:  Ramon Cacabelos
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

Review 3.  Genetic Testing in Clinical Settings.

Authors:  Nora Franceschini; Amber Frick; Jeffrey B Kopp
Journal:  Am J Kidney Dis       Date:  2018-04-11       Impact factor: 8.860

Review 4.  Genetic biomarkers in epilepsy.

Authors:  Yvonne G Weber; Anne T Nies; Matthias Schwab; Holger Lerche
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 5.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

6.  Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system.

Authors:  Alison E Fohner; Dilrini K Ranatunga; Khanh K Thai; Brian L Lawson; Neil Risch; Akinyemi Oni-Orisan; Aline T Jelalian; Allan E Rettie; Vincent X Liu; Catherine A Schaefer
Journal:  Pharmacogenet Genomics       Date:  2019-10       Impact factor: 2.089

7.  Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population.

Authors:  C-C Chang; C-C Ng; C-L Too; S-E Choon; C-K Lee; W-H Chung; S H Hussein; K-S Lim; S Murad
Journal:  Pharmacogenomics J       Date:  2016-03-01       Impact factor: 3.550

Review 8.  Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Authors:  Katarzyna Drozda; Daniel J Müller; Jeffrey R Bishop
Journal:  Pharmacotherapy       Date:  2014-02       Impact factor: 4.705

9.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875

10.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.